Cargando…

Tanshinone IIA confers protection against myocardial ischemia/reperfusion injury by inhibiting ferroptosis and apoptosis via VDAC1

Tanshinone IIA (TSN) extracted from danshen (Salvia miltiorrhiza) could protect cardiomyocytes against myocardial ischemia/reperfusion injury (IRI), however the underlying molecular mechanisms of action remain unclear. The aim of the present study was to identify the protective effects of TSN and it...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Tie, Zou, Hua-Xi, Le, Shu-Yu, Wang, Ya-Ru, Qiao, Ya-Mei, Yuan, Yong, Liu, Ji-Chun, Lai, Song-Qing, Huang, Huang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558218/
https://www.ncbi.nlm.nih.gov/pubmed/37800609
http://dx.doi.org/10.3892/ijmm.2023.5312
_version_ 1785117227970723840
author Hu, Tie
Zou, Hua-Xi
Le, Shu-Yu
Wang, Ya-Ru
Qiao, Ya-Mei
Yuan, Yong
Liu, Ji-Chun
Lai, Song-Qing
Huang, Huang
author_facet Hu, Tie
Zou, Hua-Xi
Le, Shu-Yu
Wang, Ya-Ru
Qiao, Ya-Mei
Yuan, Yong
Liu, Ji-Chun
Lai, Song-Qing
Huang, Huang
author_sort Hu, Tie
collection PubMed
description Tanshinone IIA (TSN) extracted from danshen (Salvia miltiorrhiza) could protect cardiomyocytes against myocardial ischemia/reperfusion injury (IRI), however the underlying molecular mechanisms of action remain unclear. The aim of the present study was to identify the protective effects of TSN and its mechanisms of action through in vitro studies. An anoxia/reoxygenation (A/R) injury model was established using H9c2 cells to simulate myocardial IRI in vitro. Before A/R, H9c2 cardiomyoblasts were pretreated with 8 μM TSN or 10 μM ferrostatin-1 (Fer-1) or erastin. The cell counting kit 8 (CCK-8) and lactate dehydrogenase (LDH) assay kit were used to detect the cell viability and cytotoxicity. The levels of total iron, glutathione (GSH), glutathione disulfide (GSSG), malondialdehyde (MDA), ferrous iron, caspase-3 activity, and reactive oxygen species (ROS) were assessed using commercial kit. The levels of mitochondrial membrane potential (MMP), lipid ROS, cell apoptosis, and mitochondrial permeability transition pore (mPTP) opening were detected by flow cytometry. Transmission electron microscopy (TEM) was used to observed the mitochondrial damage. Protein levels were detected by western blot analysis. The interaction between TSN and voltage-dependent anion channel 1 (VDAC1) was evaluated by molecular docking simulation. The results showed that pretreatment with TSN and Fer-1 significantly decreased cell viability, glutathione peroxidase 4 (GPX4) protein and GSH expression and GSH/GSSG ratio and inhibited upregulation of LDH activity, prostaglandin endoperoxide synthase 2 and VDAC1 protein expression, ROS levels, mitochondrial injury and GSSG induced by A/R. TSN also effectively inhibited the damaging effects of erastin treatment. Additionally, TSN increased MMP and Bcl-2/Bax ratio, while decreasing levels of apoptotic cells, activating Caspase-3 and closing the mPTP. These effects were blocked by VDAC1 overexpression and the results of molecular docking simulation studies revealed a direct interaction between TSN and VDAC1. In conclusion, TSN pretreatment effectively attenuated H9c2 cardiomyocyte damage in an A/R injury model and VDAC1-mediated ferroptosis and apoptosis served a vital role in the protective effects of TSN.
format Online
Article
Text
id pubmed-10558218
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-105582182023-10-07 Tanshinone IIA confers protection against myocardial ischemia/reperfusion injury by inhibiting ferroptosis and apoptosis via VDAC1 Hu, Tie Zou, Hua-Xi Le, Shu-Yu Wang, Ya-Ru Qiao, Ya-Mei Yuan, Yong Liu, Ji-Chun Lai, Song-Qing Huang, Huang Int J Mol Med Articles Tanshinone IIA (TSN) extracted from danshen (Salvia miltiorrhiza) could protect cardiomyocytes against myocardial ischemia/reperfusion injury (IRI), however the underlying molecular mechanisms of action remain unclear. The aim of the present study was to identify the protective effects of TSN and its mechanisms of action through in vitro studies. An anoxia/reoxygenation (A/R) injury model was established using H9c2 cells to simulate myocardial IRI in vitro. Before A/R, H9c2 cardiomyoblasts were pretreated with 8 μM TSN or 10 μM ferrostatin-1 (Fer-1) or erastin. The cell counting kit 8 (CCK-8) and lactate dehydrogenase (LDH) assay kit were used to detect the cell viability and cytotoxicity. The levels of total iron, glutathione (GSH), glutathione disulfide (GSSG), malondialdehyde (MDA), ferrous iron, caspase-3 activity, and reactive oxygen species (ROS) were assessed using commercial kit. The levels of mitochondrial membrane potential (MMP), lipid ROS, cell apoptosis, and mitochondrial permeability transition pore (mPTP) opening were detected by flow cytometry. Transmission electron microscopy (TEM) was used to observed the mitochondrial damage. Protein levels were detected by western blot analysis. The interaction between TSN and voltage-dependent anion channel 1 (VDAC1) was evaluated by molecular docking simulation. The results showed that pretreatment with TSN and Fer-1 significantly decreased cell viability, glutathione peroxidase 4 (GPX4) protein and GSH expression and GSH/GSSG ratio and inhibited upregulation of LDH activity, prostaglandin endoperoxide synthase 2 and VDAC1 protein expression, ROS levels, mitochondrial injury and GSSG induced by A/R. TSN also effectively inhibited the damaging effects of erastin treatment. Additionally, TSN increased MMP and Bcl-2/Bax ratio, while decreasing levels of apoptotic cells, activating Caspase-3 and closing the mPTP. These effects were blocked by VDAC1 overexpression and the results of molecular docking simulation studies revealed a direct interaction between TSN and VDAC1. In conclusion, TSN pretreatment effectively attenuated H9c2 cardiomyocyte damage in an A/R injury model and VDAC1-mediated ferroptosis and apoptosis served a vital role in the protective effects of TSN. D.A. Spandidos 2023-10-03 /pmc/articles/PMC10558218/ /pubmed/37800609 http://dx.doi.org/10.3892/ijmm.2023.5312 Text en Copyright: © Hu et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Hu, Tie
Zou, Hua-Xi
Le, Shu-Yu
Wang, Ya-Ru
Qiao, Ya-Mei
Yuan, Yong
Liu, Ji-Chun
Lai, Song-Qing
Huang, Huang
Tanshinone IIA confers protection against myocardial ischemia/reperfusion injury by inhibiting ferroptosis and apoptosis via VDAC1
title Tanshinone IIA confers protection against myocardial ischemia/reperfusion injury by inhibiting ferroptosis and apoptosis via VDAC1
title_full Tanshinone IIA confers protection against myocardial ischemia/reperfusion injury by inhibiting ferroptosis and apoptosis via VDAC1
title_fullStr Tanshinone IIA confers protection against myocardial ischemia/reperfusion injury by inhibiting ferroptosis and apoptosis via VDAC1
title_full_unstemmed Tanshinone IIA confers protection against myocardial ischemia/reperfusion injury by inhibiting ferroptosis and apoptosis via VDAC1
title_short Tanshinone IIA confers protection against myocardial ischemia/reperfusion injury by inhibiting ferroptosis and apoptosis via VDAC1
title_sort tanshinone iia confers protection against myocardial ischemia/reperfusion injury by inhibiting ferroptosis and apoptosis via vdac1
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558218/
https://www.ncbi.nlm.nih.gov/pubmed/37800609
http://dx.doi.org/10.3892/ijmm.2023.5312
work_keys_str_mv AT hutie tanshinoneiiaconfersprotectionagainstmyocardialischemiareperfusioninjurybyinhibitingferroptosisandapoptosisviavdac1
AT zouhuaxi tanshinoneiiaconfersprotectionagainstmyocardialischemiareperfusioninjurybyinhibitingferroptosisandapoptosisviavdac1
AT leshuyu tanshinoneiiaconfersprotectionagainstmyocardialischemiareperfusioninjurybyinhibitingferroptosisandapoptosisviavdac1
AT wangyaru tanshinoneiiaconfersprotectionagainstmyocardialischemiareperfusioninjurybyinhibitingferroptosisandapoptosisviavdac1
AT qiaoyamei tanshinoneiiaconfersprotectionagainstmyocardialischemiareperfusioninjurybyinhibitingferroptosisandapoptosisviavdac1
AT yuanyong tanshinoneiiaconfersprotectionagainstmyocardialischemiareperfusioninjurybyinhibitingferroptosisandapoptosisviavdac1
AT liujichun tanshinoneiiaconfersprotectionagainstmyocardialischemiareperfusioninjurybyinhibitingferroptosisandapoptosisviavdac1
AT laisongqing tanshinoneiiaconfersprotectionagainstmyocardialischemiareperfusioninjurybyinhibitingferroptosisandapoptosisviavdac1
AT huanghuang tanshinoneiiaconfersprotectionagainstmyocardialischemiareperfusioninjurybyinhibitingferroptosisandapoptosisviavdac1